NOVI Health

View Original

Dr Sue Anne Toh Discusses How Singaporean Youths Navigate Telehealth to Access GLP-1 RAs

See this content in the original post

Ozempic, a GLP-1 RA drug originally developed to treat type 2 diabetes, has recently gained a reputation as a “miracle” weight-loss medication. Celebrities like Oprah Winfrey and Elon Musk have reportedly used it, sparking interest worldwide and driving high demand, especially among those eager to lose weight.

In an interview on CNA Daily Cuts, Dr Sue Anne Toh, endocrinologist and Founder, CEO, and Medical Director of NOVI Health, talked about a growing trend among young Singaporeans. Reports indicate that some youths are obtaining GLP-1 RA drugs like Ozempic for weight loss through telemedicine channels by making false health declarations. Dr Toh, emphasizes on the challenges telehealth providers face and the risks for youths who may not fully understand the implications of using these medications.

Dr Toh explained that while GLP-1 RA drugs are effective for diabetes and weight management, they were never designed to be a quick fix for weight loss. In fact, using Ozempic solely for weight loss without lifestyle changes can lead to unintended side effects. Patients might experience nausea, vomiting, and even significant muscle loss if they fail to maintain a balanced diet and physical activity. 

Read more about GLP-1 RA side effects in this article.

Since muscle mass supports a healthy metabolism, loss of muscle could cause metabolic slowdowns that are counterproductive in the long run. 

Check out this article: Weight loss medication can also lead to muscle loss. Here’s how you can reduce it.

Telemedicine has made it easier for people to access GLP-1 RA drugs, but this convenience has also led to potential misuse, with some patients misrepresenting their BMI or health status to obtain prescriptions. Dr Toh emphasized the need for experienced clinicians who can discern a patient’s suitability for such drugs and provide essential guidance on diet, exercise, and overall health.

A further challenge lies in global supply constraints, which impact genuine diabetes patients relying on GLP-1 RA medications. In Singapore, NOVI Health prioritizes these patients, offering a transparent allocation process. 

Ultimately, Dr. Toh highlights that weight loss success comes not from a single “miracle” medication but from a holistic approach encompassing healthy eating, physical activity, and sufficient sleep.

Listen to the full interview here.